PharmacovigilanceOfficial

FDA orders NAION warning on all GLP-1 receptor agonist labels

🇺🇸 FDA MedWatch · Mon 09 Nov 2026

The US regulator is requiring application holders for every GLP-1 RA to add a Warnings and Precautions entry on a potential increased risk of the rare optic nerve condition NAION.

The US Food and Drug Administration has told application holders for all GLP-1 receptor agonist medicines to add information to the Warnings and Precautions section of their labelling. The information concerns a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), according to a MedWatch safety communication dated 9 November 2026.

FDA describes NAION as a rare condition that can cause acute, painless loss of vision in one eye, including permanent vision loss. It is caused by reduced blood flow to the front of the optic nerve, though the underlying cause is not completely understood. Possible risk factors listed include smoking, diabetes, high blood pressure, sleep apnoea, anaemia and kidney disease. If NAION occurs in one eye, the risk of it affecting the other eye is higher.

For clinicians, the agency advises instructing patients to report immediately any sudden onset of painless vision loss, visual field deficits or other visual disturbances in one eye. Patients with suspected NAION should be promptly referred to an ophthalmologist. Prescribers should consider stopping the GLP-1 RA in patients who develop NAION, unless the benefits clearly outweigh the risk.

Patients are told to seek medical advice straight away if they notice symptoms such as sudden vision loss in one eye, possibly on waking, blurred or missing areas of vision, colour distortion or reduced central sharpness. Those who have had a NAION event should discuss with their health professional whether to continue the medicine. FDA notes that GLP-1 RAs are widely used for type 2 diabetes and for reducing and maintaining body weight.

The text available does not give the exact label wording, the list of affected products (which it places in a table) or submission deadlines for the changes.

What it means for your team

  • MAHs of any GLP-1 RA should consult the full FDA safety communication for the product list, required wording and timelines for the Warnings and Precautions update.
  • Pharmacovigilance teams should expect more attention to reports of sudden, painless vision loss and may need to review case handling and follow-up for visual events.
  • Regulatory teams marketing these products outside the US should monitor whether other authorities take comparable action, as the source covers only FDA.

Official source: FDA MedWatch ↗

Article written by VigiEye from the official source (FDA MedWatch). AI-assisted; check the source before acting.

More Pharmacovigilance All →